Fortress Biotech, Inc.

Fortress Biotech, Inc.

FBIO
Fortress Biotech, Inc.US flagNASDAQ Capital Market
2.95
USD
-0.09
- -
98.00MMarket Cap

Total Valuation

Fortress Biotech, Inc. carries a market capitalization of 98.00M, placing it among publicly traded companies globally. Its enterprise value stands at -82.38M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Market Cap98.00M
Enterprise Value-82.38M

Share Statistics

Fortress Biotech, Inc. currently has 33.19M shares outstanding.

Shares Outstanding33.19M
Owned by Insiders (%)N/A
Owned by Institutions (%)N/A

Valuation Ratios

Fortress Biotech, Inc. trades at a trailing price-to-earnings ratio of 0.67. The price-to-sales ratio is 1.20, and the price-to-book ratio stands at -0.13.

PE Ratio0.67
PS Ratio1.20
PB Ratio-0.13
P/TBV Ratio0.45
P/FCF Ratio0.60
P/OCF Ratio0.51

Enterprise Valuation

EV / Sales2.24
EV / EBITDAN/A
EV / EBITN/A
EV / FCFN/A

Financial Position

Fortress Biotech, Inc. maintains a current ratio of 2.86, meaning it holds 2.9x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 26.50, indicating elevated leverage, while an interest coverage ratio of -6.42 demonstrates limited ability to service its debt obligations.

Current Ratio2.86
Quick Ratio2.72
Debt / Equity26.50
Debt / EBITDA-1.05
Interest Coverage-6.42

Financial Efficiency

Return on Equity (ROE)N/A
Return on Assets (ROA)47.77
Return on Invested Capital (ROIC)-29.26
Return on Capital Employed (ROCE)-22.45
Revenue Per EmployeeN/A
Employee CountN/A
Inventory Turnover2.05

Taxes

Over the trailing twelve months, Fortress Biotech, Inc. has paid 4.34M in income taxes, reflecting an effective tax rate of 3.26.

Income Tax4.34M
Effective Tax Rate3.26

Stock Price Statistics

Fortress Biotech, Inc.'s stock has gained approximately 54.45026% over the past 52 weeks. The 50-day moving average sits at 2.65, while the 200-day moving average is 2.98.

Beta (5Y)N/A
52-Week Price Change54.45026%
50-Day Moving Average2.65
200-Day Moving Average2.98
Average Volume (20 Days)N/A

Income Statement

Over the trailing twelve months, Fortress Biotech, Inc. generated 66.16M in revenue and converted that into 127.77M in net income, yielding earnings per share of 3.82. EBITDA reached -51.12M, while operating income came in at -55.81M.

Revenue66.16M
Gross Profit43.81M
Operating Income-55.81M
Pretax Income133.28M
Net Income127.77M
EBITDA-51.12M
EBIT-55.81M
Earnings Per Share (EPS)3.82

Balance Sheet

Fortress Biotech, Inc. holds 255.84M in cash and equivalents against 53.63M in total debt, resulting in a net debt position of -216.46M. Total book value stands at -623.65M, with working capital of 192.09M providing operational flexibility.

Cash & Cash Equivalents255.84M
Total Debt53.63M
Net Debt-216.46M
Equity (Book Value)-623.65M
Book Value Per Share-21.84
Working Capital192.09M

Cash Flow

Fortress Biotech, Inc. produced 157.64M in operating cash flow over the past twelve months.

Operating Cash Flow157.64M
Capital ExpendituresN/A
Free Cash Flow157.64M
FCF Per Share5.52

Margins

Fortress Biotech, Inc. operates with a gross margin of 66.22, reflecting its pricing power and cost economics. The operating margin of -84.36 and net profit margin of 193.12 provide insight into operational efficiency.

Gross Margin66.22
Operating Margin-84.36
Pretax Margin201.45
Profit Margin193.12
EBITDA Margin-77.27

Dividends & Yields

The company's payout ratio of -6.65 indicates the proportion of earnings distributed to shareholders.

Dividend Per Share0.02
Dividend YieldN/A
Payout Ratio-6.65
Shareholder Yield2.62
FCF Yield167.26

Stock Splits

Fortress Biotech, Inc.'s most recent stock split took place on October 10, 2023 with a 15:1 split ratio.

Last Split Date10/10/2023
Split Ratio15:1

Scores

Fortress Biotech, Inc. posts an Altman Z-Score of -1.99, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.

Altman Z-Score-1.99